Overview
Neuroimmunology laboratory under the department of neurology at Amrita Hospital, Kochi is the first of its kind in India- a dedicated comprehensive testing facility for autoimmune neurological disorders under a trained clinical autoimmune neurologist. These disorders can be associated with a cancer (paraneoplastic) as well without cancer association (non-paraneoplastic).
If properly investigated and diagnosed as an autoimmune neurological syndrome, it becomes potentially treatable and often fully reversible. Here comes the importance of comprehensive neuroimmunology service which can provide an early diagnosis.
Objectives
Our aim is to provide a world class testing facility, define the spectrum of these disorders in our country as well as to disseminate information among the physician community. We are planning to develop a nationwide registry for autoimmune neurological disorders and to develop a bio bank for these disorders in collaborations with physicians and institutions across the country.
When to suspect autoimmune etiology?
Here is a rough guideline about when to suspect an autoimmune neurological disorder-The clinical presentation can range from encephalitis, seizures, cognitive decline, optic neuritis, stroke like episodes, behavioral symptoms like psychosis, brainstem encephalitis characterized by cranial nerve and pyramidal involvement, ataxia, movement disorders like chorea and myoclonus ,dyskinesias, cerebellar ataxia, myelopathy, plexopathy, radiculopathy, neuropathy, autonomic neuropathy, myopathy and neuromuscular conduction defect-myasthenia.
Though the classical description of VGKC is limbic encephalitis and Moorvan's syndrome, the other presentations like PCD, GI dysmotility, parkinsonism, tremor, chorea, sensory motor neuropathy, hyponatremias, dyssomnia , hyperphagia, facio brachial dystonic seizure, other seizures and presentation mimicking CJD are well described. NMDA receptor antibodies classically associated with Psychiatric features and memory loss, orofacial dyskinesia, choreoathetoid movements, abnormal posturing or increased tone, catatonic state and central hypoventilation.
NMO IgG has expanded the spectrum of NMO to include optic neuritis and myelitis into NMO spectrum of disorder without the classical presentation of eye and spine involvement.
Clinical Features
History | Clinical examination |
|
|
|
|
|
|
| |
| |
|
Laboratory | Radiological |
|
|
|
|
|
|
|
Autoimmune etiology should be strongly sought in all neurological syndromes of unexplained etiology.
Paraneoplastic/autoimmune etiology should be considered in subacute sensory neuronopathy, cerebellar ataxia, limbic encephalitis, opsoclonus/myoclonus, encephalomyelitis, chronic gastrointestinal pseudo-obstruction and Lambert Eaton myasthenic syndrome.
Paraneoplastic antibodies are cancer specific, not disease-specific. Hence we discourage testing for single antibodies in the panel. Sometimes same patient can have multiple antibodies which in fact help us to locate cancer easily.
Laboratory
Investigations and Turn Around Time (TAT)
- Acetylcholine Receptor antibody quantitation in Serum by Indirect ELISA TAT 7 Working days.
- Adenylate Kinase 5 antibody in CSF by tissue-based Indirect Immunofluorescence Assay TAT 48 working hours.
- Adenylate Kinase 5 antibody in Serum by tissue-based Indirect Immunofluorescence Assay TAT 48 working hours.
- Agrin antibody quantitation in Serum by Competitive ELISA TAT 7 working days .
- Alpha Synuclein quantitation in CSF by Sandwich ELISA TAT 7 Working days.
- Alpha Synuclein quantitation in Serum by Sandwich ELISA TAT 7 Working days
- Autoimmune Atypical Parkinsonism antibody panel in CSF
- ANNA-1(anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody -2.
- ANNA-3 Anti Neuronal Nuclear Antibody- 3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje Cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje Cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody.
- IgLON5 Antibody
- LGI-1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- Unclassified Neuronal Antibody
TAT 24 working hours
- Autoimmune Atypical Parkinsonism antibody panel in Serum
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody -2.
- ANNA-3 Anti Neuronal Nuclear Antibody -3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje Cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje Cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody.
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- IgLON5 Antibody
- LGI- 1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated) 2 /13
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- Unclassified Neuronal Antibody
TAT 24 working hours
- Autoimmune Dementia Evaluation Panel – Optimised
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody1 in Serum
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody 2 in Serum
- ANNA-3 Anti Neuronal Nuclear Antibody 3 in Serum
- AGNA-1 Anti Glial Nuclear Antibody-1 in Serum
- PCA-2 Purkinje Cell Cytoplasmic Antibody-2 in Serum
- PCA-Tr Purkinje Cell Cytoplasmic Antibody-Tr in Serum
- Amphiphysin Antibody in Serum
- CRMP-5{Collapsin Response Mediator Protein-5} (Anti CV-2) Antibody in Serum
- Ma2/Ta Antibody in Serum
- GABA A Receptor Antibody in Serum
- GFAP Antibody in CSF
- DPPX-6 Receptor Antibody in Serum
- Glycine Receptor Antibody in Serum
- IgLON5 Antibody in Serum
- LGI-1(Leucine-rich glioma- inactivated Protein-1) Antibody (VGKC associated) in Serum
- CASPR-2(Contactin-associated protein-2) Antibody (VGKC associated) in Serum
- NMDA (NR1) Receptor Antibody in CSF
- .AMPA1 Receptor Antibody in CSF
- AMPA2 Receptor Antibody in CSF
- GABA B Receptor Antibody in CSF
- Zic 4 Antibody in Serum
- Voltage-Gated Calcium Channel (VGCC) Antibody quantitation in Serum
- Unclassified Neuronal Antibody in Serum
TAT 7 Working days
- Autoimmune Dementia Evaluation Panel in CSF
- ANNA-1(anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody -2.
- ANNA-3 Anti Neuronal Nuclear Antibody- 3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje Cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje Cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody.
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- GABA A Receptor Antibody
- GFAP Antibody
- DPPX-6 Receptor Antibody
- Glycine Receptor Antibody
- IgLON5 Antibody
- LGI-1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- NMDA (NR1) Receptor Antibody
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- GABA B Receptor Antibody
- Zic 4 Antibody
- Unclassified Neuronal Antibody
TAT 48 Working hours
- Autoimmune Dementia Evaluation Panel in Serum
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody -2.
- ANNA-3 Anti Neuronal Nuclear Antibody -3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody.
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- GABA A Receptor Antibody
- GFAP Antibody
- DPPX -6 Receptor Antibody
- Glycine Receptor Antibody
- IgLON5 Antibody
- LGI-1(Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- NMDA (NR1) Receptor Antibody
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- GABA B Receptor Antibody
- Voltage-Gated Calcium Channel (VGCC) Antibody quantitation
- Zic 4 Antibody 23. Unclassified Neuronal Antibody
TAT 7 Working days
- Autoimmune Encephalitis Panel of antibodies in CSF by cell-based Indirect Immunofluorescence Assay
- GABA B Receptor Antibody
- LGI 1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR 2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- NMDA (NR1) Receptor Antibody
TAT 24 working hours
- Autoimmune Encephalitis Panel of antibodies in Serum by cell-based Indirect Immunofluorescence Assay
- GABA B Receptor Antibody
- LGI 1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR 2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- NMDA (NR1) Receptor Antibody
TAT 24 working hours
- Autoimmune Epilepsy Profile in CSF
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody-1
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody-2.
- ANNA-3 Anti Neuronal Nuclear Antibody 3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody. 4 /13
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- LGI-1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- NMDA (NR1) Receptor Antibody
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- GABA B Receptor Antibody
- GABA A Receptor Antibody
- GFAP Antibody
- DPPX-6 Receptor Antibody
- Glycine Receptor Antibody
- Unclassified Neuronal Antibody
TAT 24 working hours
- Autoimmune Epilepsy Profile in Serum
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody-2.
- ANNA-3 Anti Neuronal Nuclear Antibody-3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody.
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- LGI-1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- NMDA (NR1) Receptor Antibody
- AMPA1 Receptor Antibody
- AMPA2 Receptor Antibody
- GABA B Receptor Antibody
- GABA A Receptor Antibody
- GFAP Antibody
- DPPX-6 Receptor Antibody
- Glycine Receptor Antibody
- Unclassified Neuronal Antibody
TAT 24 working hours
- Autoimmune Neuropathy Evaluation Panel in Serum
- Neurofascin 140 Antibody quantitation by Competitive ELISA
- Neurofascin 155 Antibody quantitation by Competitive ELISA
- Neurofascin 186 Antibody quantitation by Competitive ELISA
- MAG antibody quantitation by Sandwich ELISA
- Neuronal Antibody detection
- VGKC associated LGI-1 and CASPR-2 Antibody detection
- GAD65 Antibody quantitation
TAT 15 Working days
- CARP VIII (Carbonic Anhydrase – Related Protein VIII) antibody detection in CSF by tissue – based Indirect Immunofluorescence Assay
TAT 48 working hours - CARP VIII (Carbonic Anhydrase – Related Protein VIII) antibody detection in Serum by tissue – based Indirect Immunofluorescence Assay
TAT 48 working hours - CNS inflammation evaluation panel by Isoelectric focusing and immunofixation method
- Serum albumin quantitation
- Serum IgG quantitation
- CSF albumin quantitation
- CSF IgG quantitation
- CSF IgG index- formula-based calculation
- CSF IgG synthesis rate- formula-based calculation
- CSF IgG Intrathecal synthesis rate- formula-based calculation
- Albumin index- formula-based calculation
- Serum Oligoclonal Bands
- CSF Oligoclonal Bands Paired Serum and CSF samples are necessary.
CSF sample to be collected in polypropylene tube
TAT 7 working days
- CNS inflammation evaluation panel- Extended by Isoelectric focusing – immunofixation method and Indirect Immunofluorescence Assay
- Serum albumin quantitation
- Serum IgG quantitation
- CSF albumin quantitation
- CSF IgG quantitation
- CSF IgG index- formula-based calculation
- CSF IgG synthesis rate- formula-based calculation
- CSF IgG Intrathecal synthesis rate- formula-based calculation
- Albumin index- formula-based calculation
- CSFIgG/ CSF albumin ratio
- Serum Oligoclonal Bands
- CSF Oligoclonal Bands
- Serum Neuronal antibody
- CSF Neuronal antibody
Paired Serum and CSF samples are necessary.
CSF sample to be collected in polypropylene tube
TAT 7 working days.
- DPPX -6 (Dipeptidyl Aminopeptidase like Protein 6) antibody detection in CSF by tissue based Indirect Immunofluorescence Assay and confirmation of positive by cell-based immunofluorescence assay
TAT 24 working hours - DPPX -6 (Dipeptidyl Aminopeptidase like Protein 6) antibody detection in Serum by tissuebased Indirect Immunofluorescence Assay and confirmation of positive by cell-based immunofluorescence assay
TAT 24 working hours
Contact Us
Address: Dr.Sudheeran Kannoth, Neuroimmunology laboratory (T6F3) Amrita Institute of Medical Sciences(Amrita Hospital), Ponekkara PO 682041, or Elamakkara PO 682026 Kochi, Kerala, India
Phone:+91 484 285 1234, 0484 6681234 Extension - 1356 & 6318
Mobile: 09400998656 (Dr. Annamma Mathai-on call mobile)
Email: neuroimmunology@aims.amrita.edu
Overview
Neuroimmunology laboratory under the department of neurology at Amrita Hospital, Kochi is the first of its kind in India- a dedicated comprehensive testing facility for autoimmune neurological disorders under a trained clinical autoimmune neurologist. These disorders can be associated with a cancer (paraneoplastic) as well without cancer association (non-paraneoplastic).
If properly investigated and diagnosed as an autoimmune neurological syndrome, it becomes potentially treatable and often fully reversible. Here comes the importance of comprehensive neuroimmunology service which can provide an early diagnosis.
Objectives
Our aim is to provide a world class testing facility, define the spectrum of these disorders in our country as well as to disseminate information among the physician community. We are planning to develop a nationwide registry for autoimmune neurological disorders and to develop a bio bank for these disorders in collaborations with physicians and institutions across the country.
When to suspect autoimmune etiology?
Here is a rough guideline about when to suspect an autoimmune neurological disorder-The clinical presentation can range from encephalitis, seizures, cognitive decline, optic neuritis, stroke like episodes, behavioral symptoms like psychosis, brainstem encephalitis characterized by cranial nerve and pyramidal involvement, ataxia, movement disorders like chorea and myoclonus ,dyskinesias, cerebellar ataxia, myelopathy, plexopathy, radiculopathy, neuropathy, autonomic neuropathy, myopathy and neuromuscular conduction defect-myasthenia.
Though the classical description of VGKC is limbic encephalitis and Moorvan's syndrome, the other presentations like PCD, GI dysmotility, parkinsonism, tremor, chorea, sensory motor neuropathy, hyponatremias, dyssomnia , hyperphagia, facio brachial dystonic seizure, other seizures and presentation mimicking CJD are well described. NMDA receptor antibodies classically associated with Psychiatric features and memory loss, orofacial dyskinesia, choreoathetoid movements, abnormal posturing or increased tone, catatonic state and central hypoventilation.
NMO IgG has expanded the spectrum of NMO to include optic neuritis and myelitis into NMO spectrum of disorder without the classical presentation of eye and spine involvement.
Clinical Features
History | Clinical examination |
|
|
|
|
|
|
| |
| |
|
Laboratory | Radiological |
|
|
|
|
|
|
|
Autoimmune etiology should be strongly sought in all neurological syndromes of unexplained etiology.
Paraneoplastic/autoimmune etiology should be considered in subacute sensory neuronopathy, cerebellar ataxia, limbic encephalitis, opsoclonus/myoclonus, encephalomyelitis, chronic gastrointestinal pseudo-obstruction and Lambert Eaton myasthenic syndrome.
Paraneoplastic antibodies are cancer specific, not disease-specific. Hence we discourage testing for single antibodies in the panel. Sometimes same patient can have multiple antibodies which in fact help us to locate cancer easily.
Laboratory
Investigations and Turn Around Time (TAT)
- Acetylcholine Receptor antibody quantitation in Serum by Indirect ELISA TAT 7 Working days.
- Adenylate Kinase 5 antibody in CSF by tissue-based Indirect Immunofluorescence Assay TAT 48 working hours.
- Adenylate Kinase 5 antibody in Serum by tissue-based Indirect Immunofluorescence Assay TAT 48 working hours.
- Agrin antibody quantitation in Serum by Competitive ELISA TAT 7 working days .
- Alpha Synuclein quantitation in CSF by Sandwich ELISA TAT 7 Working days.
- Alpha Synuclein quantitation in Serum by Sandwich ELISA TAT 7 Working days
- Autoimmune Atypical Parkinsonism antibody panel in CSF
- ANNA-1(anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody -2.
- ANNA-3 Anti Neuronal Nuclear Antibody- 3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje Cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje Cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody.
- IgLON5 Antibody
- LGI-1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- Unclassified Neuronal Antibody
TAT 24 working hours
- Autoimmune Atypical Parkinsonism antibody panel in Serum
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody -2.
- ANNA-3 Anti Neuronal Nuclear Antibody -3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje Cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje Cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody.
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- IgLON5 Antibody
- LGI- 1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated) 2 /13
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- Unclassified Neuronal Antibody
TAT 24 working hours
- Autoimmune Dementia Evaluation Panel – Optimised
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody1 in Serum
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody 2 in Serum
- ANNA-3 Anti Neuronal Nuclear Antibody 3 in Serum
- AGNA-1 Anti Glial Nuclear Antibody-1 in Serum
- PCA-2 Purkinje Cell Cytoplasmic Antibody-2 in Serum
- PCA-Tr Purkinje Cell Cytoplasmic Antibody-Tr in Serum
- Amphiphysin Antibody in Serum
- CRMP-5{Collapsin Response Mediator Protein-5} (Anti CV-2) Antibody in Serum
- Ma2/Ta Antibody in Serum
- GABA A Receptor Antibody in Serum
- GFAP Antibody in CSF
- DPPX-6 Receptor Antibody in Serum
- Glycine Receptor Antibody in Serum
- IgLON5 Antibody in Serum
- LGI-1(Leucine-rich glioma- inactivated Protein-1) Antibody (VGKC associated) in Serum
- CASPR-2(Contactin-associated protein-2) Antibody (VGKC associated) in Serum
- NMDA (NR1) Receptor Antibody in CSF
- .AMPA1 Receptor Antibody in CSF
- AMPA2 Receptor Antibody in CSF
- GABA B Receptor Antibody in CSF
- Zic 4 Antibody in Serum
- Voltage-Gated Calcium Channel (VGCC) Antibody quantitation in Serum
- Unclassified Neuronal Antibody in Serum
TAT 7 Working days
- Autoimmune Dementia Evaluation Panel in CSF
- ANNA-1(anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody -2.
- ANNA-3 Anti Neuronal Nuclear Antibody- 3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje Cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje Cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody.
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- GABA A Receptor Antibody
- GFAP Antibody
- DPPX-6 Receptor Antibody
- Glycine Receptor Antibody
- IgLON5 Antibody
- LGI-1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- NMDA (NR1) Receptor Antibody
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- GABA B Receptor Antibody
- Zic 4 Antibody
- Unclassified Neuronal Antibody
TAT 48 Working hours
- Autoimmune Dementia Evaluation Panel in Serum
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody -2.
- ANNA-3 Anti Neuronal Nuclear Antibody -3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody.
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- GABA A Receptor Antibody
- GFAP Antibody
- DPPX -6 Receptor Antibody
- Glycine Receptor Antibody
- IgLON5 Antibody
- LGI-1(Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- NMDA (NR1) Receptor Antibody
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- GABA B Receptor Antibody
- Voltage-Gated Calcium Channel (VGCC) Antibody quantitation
- Zic 4 Antibody 23. Unclassified Neuronal Antibody
TAT 7 Working days
- Autoimmune Encephalitis Panel of antibodies in CSF by cell-based Indirect Immunofluorescence Assay
- GABA B Receptor Antibody
- LGI 1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR 2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- NMDA (NR1) Receptor Antibody
TAT 24 working hours
- Autoimmune Encephalitis Panel of antibodies in Serum by cell-based Indirect Immunofluorescence Assay
- GABA B Receptor Antibody
- LGI 1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR 2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- NMDA (NR1) Receptor Antibody
TAT 24 working hours
- Autoimmune Epilepsy Profile in CSF
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody-1
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody-2.
- ANNA-3 Anti Neuronal Nuclear Antibody 3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody. 4 /13
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- LGI-1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- NMDA (NR1) Receptor Antibody
- AMPA 1 Receptor Antibody
- AMPA 2 Receptor Antibody
- GABA B Receptor Antibody
- GABA A Receptor Antibody
- GFAP Antibody
- DPPX-6 Receptor Antibody
- Glycine Receptor Antibody
- Unclassified Neuronal Antibody
TAT 24 working hours
- Autoimmune Epilepsy Profile in Serum
- ANNA-1 (anti-Hu) Anti Neuronal Nuclear Antibody-1.
- ANNA-2 (anti-Ri) Anti Neuronal Nuclear Antibody-2.
- ANNA-3 Anti Neuronal Nuclear Antibody-3.
- AGNA-1 Anti Glial Nuclear Antibody-1.
- PCA-2 Purkinje cell Cytoplasmic Antibody-2.
- PCA-Tr Purkinje cell Cytoplasmic Antibody-Tr.
- Amphiphysin Antibody.
- CRMP-5{Collapsin Response Mediator Protein-5} (CV-2) Antibody.
- Ma2/Ta Antibody
- LGI-1 (Leucine-rich Glioma- Inactivated Protein-1) Antibody (VGKC associated)
- CASPR-2 (Contactin-Associated Protein-2) Antibody (VGKC associated)
- NMDA (NR1) Receptor Antibody
- AMPA1 Receptor Antibody
- AMPA2 Receptor Antibody
- GABA B Receptor Antibody
- GABA A Receptor Antibody
- GFAP Antibody
- DPPX-6 Receptor Antibody
- Glycine Receptor Antibody
- Unclassified Neuronal Antibody
TAT 24 working hours
- Autoimmune Neuropathy Evaluation Panel in Serum
- Neurofascin 140 Antibody quantitation by Competitive ELISA
- Neurofascin 155 Antibody quantitation by Competitive ELISA
- Neurofascin 186 Antibody quantitation by Competitive ELISA
- MAG antibody quantitation by Sandwich ELISA
- Neuronal Antibody detection
- VGKC associated LGI-1 and CASPR-2 Antibody detection
- GAD65 Antibody quantitation
TAT 15 Working days
- CARP VIII (Carbonic Anhydrase – Related Protein VIII) antibody detection in CSF by tissue – based Indirect Immunofluorescence Assay
TAT 48 working hours - CARP VIII (Carbonic Anhydrase – Related Protein VIII) antibody detection in Serum by tissue – based Indirect Immunofluorescence Assay
TAT 48 working hours - CNS inflammation evaluation panel by Isoelectric focusing and immunofixation method
- Serum albumin quantitation
- Serum IgG quantitation
- CSF albumin quantitation
- CSF IgG quantitation
- CSF IgG index- formula-based calculation
- CSF IgG synthesis rate- formula-based calculation
- CSF IgG Intrathecal synthesis rate- formula-based calculation
- Albumin index- formula-based calculation
- Serum Oligoclonal Bands
- CSF Oligoclonal Bands Paired Serum and CSF samples are necessary.
CSF sample to be collected in polypropylene tube
TAT 7 working days
- CNS inflammation evaluation panel- Extended by Isoelectric focusing – immunofixation method and Indirect Immunofluorescence Assay
- Serum albumin quantitation
- Serum IgG quantitation
- CSF albumin quantitation
- CSF IgG quantitation
- CSF IgG index- formula-based calculation
- CSF IgG synthesis rate- formula-based calculation
- CSF IgG Intrathecal synthesis rate- formula-based calculation
- Albumin index- formula-based calculation
- CSFIgG/ CSF albumin ratio
- Serum Oligoclonal Bands
- CSF Oligoclonal Bands
- Serum Neuronal antibody
- CSF Neuronal antibody
Paired Serum and CSF samples are necessary.
CSF sample to be collected in polypropylene tube
TAT 7 working days.
- DPPX -6 (Dipeptidyl Aminopeptidase like Protein 6) antibody detection in CSF by tissue based Indirect Immunofluorescence Assay and confirmation of positive by cell-based immunofluorescence assay
TAT 24 working hours - DPPX -6 (Dipeptidyl Aminopeptidase like Protein 6) antibody detection in Serum by tissuebased Indirect Immunofluorescence Assay and confirmation of positive by cell-based immunofluorescence assay
TAT 24 working hours
Contact Us
Address: Dr.Sudheeran Kannoth, Neuroimmunology laboratory (T6F3) Amrita Institute of Medical Sciences(Amrita Hospital), Ponekkara PO 682041, or Elamakkara PO 682026 Kochi, Kerala, India
Phone:+91 484 285 1234, 0484 6681234 Extension - 1356 & 6318
Mobile: 09400998656 (Dr. Annamma Mathai-on call mobile)
Email: neuroimmunology@aims.amrita.edu